Provided by Tiger Fintech (Singapore) Pte. Ltd.

Longeveron Inc

1.61
+0.05003.21%
Post-market: 1.60-0.0100-0.62%16:31 EDT
Volume:134.08K
Turnover:213.04K
Market Cap:24.03M
PE:-0.62
High:1.61
Open:1.55
Low:1.54
Close:1.56
Loading ...

Longeveron Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
02 Mar

Longeveron Inc. Reports Strong 2024 Financial Growth

TIPRANKS
·
01 Mar

Longeveron reports Q4 revenue $700,000, consensus $637,500

TIPRANKS
·
01 Mar

Longeveron FY 2024 GAAP EPS $(2.62) Beats $(3.53) Estimate, Sales $2.392M Beat $2.143M Estimate

Benzinga
·
01 Mar

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
01 Mar

Press Release: Longeveron(R) Announces Full-Year 2024 Financial Results and Provides Business Update

Dow Jones
·
01 Mar

Longeveron management to meet with Maxim

TIPRANKS
·
26 Feb

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

GlobeNewswire
·
21 Feb

Longeveron Cellular Therapy Granted International Non-Proprietary Name

MT Newswires Live
·
18 Feb

Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce

TIPRANKS
·
18 Feb

Longeveron® Announces World Health Organization Approval of “Laromestrocel” as International Non-Proprietary Name for Stem Cell Therapy Lomecel-B™

THOMSON REUTERS
·
18 Feb

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

GlobeNewswire
·
18 Feb

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

GlobeNewswire
·
14 Feb

Longeveron Board Member Neil Hare Resigns

TIPRANKS
·
31 Jan

Longeveron to Present at Biotech Showcase 2025

GlobeNewswire
·
18 Dec 2024

Roth Initiates Longeveron at Buy With $10 Price Target

MT Newswires Live
·
06 Dec 2024

Longeveron initiated with a Buy at Roth MKM

TIPRANKS
·
06 Dec 2024

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

GlobeNewswire
·
02 Dec 2024

Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Nov 2024

Longeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial Position

TIPRANKS
·
25 Nov 2024